{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:30:32Z","timestamp":1771389032626,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Rapid initiation of ART after HIV diagnosis is recommended for individual and public health benefits. However, certain clinical and ART-related considerations hinder immediate initiation of therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An open-label, single-arm, single-centre 48-week prospective clinical trial involving ART-na\u00efve HIV-diagnosed adults who started bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) within a week from the first hospital visit, before the availability of baseline laboratory and genotype results. The primary aim was to determine the proportion of people with at least one condition that would hinder immediate initiation of any recommended ART regimen other than BIC\/FTC\/TAF. Clinicaltrials.gov: NCT04416906.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 100 participants: 79% men, 64% from Latin America, median age 32 years. According to European AIDS Clinical Society (EACS) and US Department of Health and Human Services 2023 guidelines, 11% (95%CI 6; 19) of participants had at least one condition that made any ART different from BIC\/FTC\/TAF less appropriate for a rapid ART strategy. Seventy-nine percent of the people started BIC\/FTC\/TAF within the first 48 hours of their first hospital visit. There were 16 early discontinuations (11 lost to follow-up). By week 48, 92% (95%CI 86; 98) of the participants of the ITT population with observed data achieved viral suppression. Eight grade 3\u20134 adverse events (AEs), five serious AEs and six ART-related AEs were identified. Adherence remained high.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>BIC\/FTC\/TAF is an optimal treatment for rapid initiation of ART. However, additional strategies to improve retention in care must be implemented.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae235","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:19:26Z","timestamp":1721873966000},"page":"2343-2353","source":"Crossref","is-referenced-by-count":3,"title":["Rapid initiation of bictegravir\/emtricitabine\/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-5000","authenticated-orcid":false,"given":"Ainoa","family":"Ugarte","sequence":"first","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"De La Mora","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"De Lazzari","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Chivite","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Solbes","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-3711","authenticated-orcid":false,"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Foncillas","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Calvo","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain"},{"name":"University of Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"Suppl 1","key":"2024090302262966500_dkae235-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12708","article-title":"Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps","volume":"20","author":"Boyd","year":"2019","journal-title":"HIV Med"},{"key":"2024090302262966500_dkae235-B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","article-title":"Benefits and risks of rapid initiation of antiretroviral therapy","volume":"32","author":"Ford","year":"2018","journal-title":"AIDS"},{"key":"2024090302262966500_dkae235-B3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.24875\/AIDSRev.M19000027","article-title":"Rapid initiation of antiretroviral therapy after HIV diagnosis","volume":"21","author":"Garc\u00eda-Deltoro","year":"2019","journal-title":"AIDS Rev"},{"key":"2024090302262966500_dkae235-B4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0140-6736(08)61697-9","article-title":"Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model","volume":"373","author":"Granich","year":"2009","journal-title":"Lancet"},{"key":"2024090302262966500_dkae235-B5","doi-asserted-by":"crossref","first-page":"e25455","DOI":"10.1002\/jia2.25455","article-title":"What do the universal test and treat trials tell us about the path to HIV epidemic control?","volume":"23","author":"Havlir","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2024090302262966500_dkae235-B6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"2024090302262966500_dkae235-B7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0000000000002124","article-title":"RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population","volume":"33","author":"Coffey","year":"2019","journal-title":"AIDS"},{"key":"2024090302262966500_dkae235-B8","doi-asserted-by":"crossref","first-page":"ofy104","DOI":"10.1093\/ofid\/ofy104","article-title":"Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States","volume":"5","author":"Colasanti","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024090302262966500_dkae235-B9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/aid.2019.0206","article-title":"Short communication: early antiretroviral therapy is associated with better viral suppression and less HIV drug resistance after implementation of universal treatment in South Africa","volume":"36","author":"Dorward","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024090302262966500_dkae235-B10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"2024090302262966500_dkae235-B11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study","volume":"197","author":"Emery","year":"2008","journal-title":"J Infect Dis"},{"key":"2024090302262966500_dkae235-B12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1086\/529523","article-title":"Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up","volume":"197","author":"Lundgren","year":"2008","journal-title":"J Infect Dis"},{"key":"2024090302262966500_dkae235-B13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0000000000001134","article-title":"The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting","volume":"74","author":"Pilcher","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024090302262966500_dkae235-B14","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/QAD.0000000000002937","article-title":"Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression","volume":"35","author":"Pathela","year":"2021","journal-title":"AIDS"},{"key":"2024090302262966500_dkae235-B15","doi-asserted-by":"crossref","first-page":"e1002015","DOI":"10.1371\/journal.pmed.1002015","article-title":"Initiating antiretroviral therapy for HIV at a patient\u2019s first clinic visit: the RapIT randomized controlled trial","volume":"13","author":"Rosen","year":"2016","journal-title":"PLoS Med"},{"key":"2024090302262966500_dkae235-B16","doi-asserted-by":"crossref","first-page":"e1002357","DOI":"10.1371\/journal.pmed.1002357","article-title":"Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial","volume":"14","author":"Koenig","year":"2017","journal-title":"PLoS Med"},{"key":"2024090302262966500_dkae235-B17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jama.2018.1818","article-title":"Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical TrialEffect on viral suppression of same-day ART vs care referral after home HIV testing in LesothoEffect on viral suppression of same-day ART vs care referral after home HIV testing in Lesotho","volume":"319","author":"Labhardt","year":"2018","journal-title":"JAMA"},{"key":"2024090302262966500_dkae235-B18","article-title":"Initial combination regimen for ART-na\u00efve adult PLWH [Internet]","author":"European AIDS Clinical Society (EACS) guidelines","year":"2023"},{"key":"2024090302262966500_dkae235-B19","article-title":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]","author":"Department of Health and Human Services","year":"2022"},{"key":"2024090302262966500_dkae235-B20","article-title":"National AIDS Plan regarding antiretroviral treatment in adults infected by the human immunodeficiency virus [Internet]","author":"Document of consensus from GeSIDA","year":"2023"},{"key":"2024090302262966500_dkae235-B21","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV [Internet]","author":"Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios","year":"2022"},{"key":"2024090302262966500_dkae235-B22","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults 2020. Recommendations of the international antiviral society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2024090302262966500_dkae235-B23","article-title":"Managing advanced HIV disease and rapid initiation of antiretroviral therapy [Internet]","author":"World Health Organization Guidelines","year":"2017"},{"key":"2024090302262966500_dkae235-B24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"2024090302262966500_dkae235-B25","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2024090302262966500_dkae235-B26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1157\/13081566","article-title":"Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire","volume":"23","author":"Condes","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2024090302262966500_dkae235-B27","article-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. [Internet]","author":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS","year":"2017"},{"key":"2024090302262966500_dkae235-B28","article-title":"HIV drug resistance database [Internet]","author":"Stanford University","year":"2023"},{"key":"2024090302262966500_dkae235-B29","article-title":"HIV drug interactions. Interaction checker [Internet]","author":"University of Liverpool","year":"2023"},{"key":"2024090302262966500_dkae235-B30","article-title":"Initial combination regimen for ART-na\u00efve adult PLWH [Internet]","author":"European AIDS Clinical Society (EACS) Guidelines","year":"2019"},{"key":"2024090302262966500_dkae235-B31","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. [Internet]","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2019"},{"key":"2024090302262966500_dkae235-B32","article-title":"PASS 15 power analysis and sample size software. NCSS, LLC: Kaysville, Utah, USA","author":"NCSS","year":"2017"},{"key":"2024090302262966500_dkae235-B33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024090302262966500_dkae235-B34","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2024090302262966500_dkae235-B35","volume-title":"Stata Statistical Software: Release 18","author":"StataCorp","year":"2023"},{"issue":"Suppl 1","key":"2024090302262966500_dkae235-B36","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/ofid\/ofab466.075","article-title":"High rates of virologic suppression with DTG\/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load &gt;500,000 c\/mL: 48-week subgroup analysis of the STAT study","volume":"8","author":"Rolle","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024090302262966500_dkae235-B37","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/cid\/ciz1213","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study","volume":"71","author":"Huhn","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024090302262966500_dkae235-B38","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"AIDS"},{"key":"2024090302262966500_dkae235-B39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkad008","article-title":"Same-day initiation of bictegravir\/emtricitabine\/tenofovir alafenamide: week 48 results of the FAST study-IMEA 055","volume":"78","author":"Bachelard","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024090302262966500_dkae235-B40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024090302262966500_dkae235-B41","author":"Cordova"},{"key":"2024090302262966500_dkae235-B42","doi-asserted-by":"crossref","first-page":"ofad526","DOI":"10.1093\/ofid\/ofad526","article-title":"Virologic response to dolutegravir plus lamivudine in people with suppressed human immunodeficiency virus type 1 and historical M184V\/I: a systematic literature review and meta-analysis","volume":"10","author":"Kabra","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024090302262966500_dkae235-B43","doi-asserted-by":"crossref","first-page":"2000236","DOI":"10.2807\/1560-7917.ES.2021.26.25.2000236","article-title":"HIV\/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018","volume":"26","author":"P\u00e9rez-Latorre","year":"2021","journal-title":"Euro Surveill"},{"key":"2024090302262966500_dkae235-B44","doi-asserted-by":"crossref","first-page":"e10460","DOI":"10.1371\/journal.pone.0010460","article-title":"Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort","volume":"5","author":"Ford","year":"2010","journal-title":"PLoS ONE"},{"key":"2024090302262966500_dkae235-B45","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1097\/QAD.0000000000001250","article-title":"High levels of retention in care with streamlined care and universal test and treat in East Africa","volume":"30","author":"Brown","year":"2016","journal-title":"AIDS"},{"key":"2024090302262966500_dkae235-B46","doi-asserted-by":"crossref","first-page":"ofz161","DOI":"10.1093\/ofid\/ofz161","article-title":"A care continuum of immediate ART for newly diagnosed patients and patients presenting later care at a federally qualified health center in New Orleans","volume":"6","author":"Halperin","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024090302262966500_dkae235-B47","doi-asserted-by":"crossref","first-page":"w20535","DOI":"10.4414\/smw.2021.20535","article-title":"\u201cLinkage to care\u201d among people living with HIV-definition in the era of \u201cuniversal test and treat\u201d in sub-Sahara African setting","volume":"151","author":"Senkoro","year":"2021","journal-title":"Swiss Med Wkly"},{"key":"2024090302262966500_dkae235-B48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13063-023-07404-y","article-title":"Predictors of participant retention in a community-based HIV prevention cohort: perspectives from the HPTN 071 (PopART) study","volume":"24","author":"Bell-Mandla","year":"2023","journal-title":"Trials"},{"key":"2024090302262966500_dkae235-B49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","article-title":"A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies","volume":"71","author":"Curno","year":"2016","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2343\/58998551\/dkae235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2343\/58998551\/dkae235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:27:20Z","timestamp":1725330440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/9\/2343\/7719011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae235","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,24]]}}}